News roundup Tuesday, May 28

The latest from BioStock

» Prolight Diagnostics strengthens the board with experienced business developer
» Chordate Medical's CEO: "We are building step by step"
» AdjuTec advances towards phase I with regulatory green light
» Prolight Diagnostics CSO comments on latest data
» CLS revises strategy – increases focus on neurosurgery

Read BioStock's weekly newsletter for v.21 here.

The latest news of the day

announces a public cash offer to the shareholders and holders of American Depositary Receipts in Calliditas Therapeutics. Read moreCalliditas' board of directors recommends that shareholders accept the takeover offer. Read more.

Realheart receives a Vinnova grant of SEK 4 million together with KTH. Read more.

Q-line announces that the technology behind Podler valued at SEK 70 million. Read more.

InDex Pharmaceuticals publishes company description in connection with the reverse acquisition of Flerie Invest. Read more.

PolarCools The board of directors decides on a guaranteed rights issue of units of approximately SEK 16,54 million. Read more.

CombiGene announces that Annika Ericsson takes over the role of Chief Scientific Officer. Read more.

Cessatech reports that the first patient has been dosed in the 0202 safety study of the lead product candidate CT001. Read more.

Active Biotech will present clinical activity and safety of naptumomab and docetaxel at ASCO 2024. Read more.

Mendus has decided to reverse the company's shares. Read more.

Redsense Medical announces that the company's CEO is leaving his position. Read more.

Observe Medical make an early launch of UnoMeter Safety Plus. Read more.